Impaired virologic response to highly active antiretroviral therapy associated with ongoing injection drug use

Journal of Acquired Immune Deficiency Syndromes

Volumn 32, Issue 5, 2003, Pages 522-526

  Palepu, Anita ^a,b   Tyndall, Mark ^c   Yip, Benita ^c   O'Shaughnessy, Michael V ^c   Hogg, Robert S ^c,d   Montaner, Julio S G ^b,c  

^a CENTRE FOR HEALTH EVALUATION AND OUTCOME SCIENCES   (Canada)

^b Department of Medicine ^*  (Canada)

^c UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^d BRITISH COLUMBIA CENTRE FOR EXCELLENCE IN HIV AIDS   (Canada)

Author keywords

Anti HIV agents; HIV infections; Human; Intravenous; Logistic regression models; Substance abuse

Indexed keywords

ANTIRETROVIRUS AGENT; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; VIRUS RNA;

ADULT; AGE; ARTICLE; CANADA; CONTROLLED STUDY; FEMALE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INTRAVENOUS DRUG ABUSE; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; PATIENT COMPLIANCE; PHARMACY; POPULATION RESEARCH; PRESCRIPTION; PRIORITY JOURNAL; QUESTIONNAIRE; SOCIOECONOMICS; TREATMENT FAILURE; VIRUS INHIBITION; VIRUS LOAD;

EID: 0037446294     PISSN: 15254135     EISSN: None     Source Type: Journal    
DOI: 10.1097/00126334-200304150-00009     Document Type: Article

References (31)

1. Hogg RS, Heath KV, Yip B, et al. Improved survival among HIV-infected individuals following initiation of antiretroviral therapy. JAMA. 1998;279:450-454.
2. Hogg RS, Yip B, Kully C, et al. Improved survival among HIV-infected patients after initiation of triple-drug antiretroviral regimens. CMAJ. 1999;160:659-665.
3. Hammer SM, Squires KE, Hughes MD, et al. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. AIDS Clinical Trials Group 320 Study Team. N Engl J Med. 1997;337:725-733.
4. Palella FJ, Jr, Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med. 1998;338:853-860.
5. Quinn TC, Wawer MJ, Sewankambo N, et al. Viral load and heterosexual transmission of human immunodeficiency virus type 1. Rakai Project Study Group. N Engl J Med. 2000;342:921-929.
6. Vernazza PL, Gilliam BL, Flepp M, et al. Effect of antiviral treatment on the shedding of HIV-1 in semen. AIDS. 1997;11:1249-1254.
7. Cardo DM, Culver DH, Ciesielski CA, et al. A case-control study of HIV seroconversion in health care workers after percutaneous exposure. Centers for Disease Control and Prevention Needlestick Surveillance Group. N Engl J Med. 1997;337:1485-1490.
8. Wainberg MA, Friedland G. Public health implications of antiretroviral therapy and HIV drug resistance. JAMA. 1998;279:1977-1983.
9. Paterson DL, Swindells S, Mohr J, et al. Adherence to protease inhibitor therapy and outcomes in patients with HIV infection. Ann Intern Med. 2000;133:21-30.
10. HIV/AIDS update. Year end 2000. Vancouver: British Columbia Centre for Disease Control, 2000.
11. HIV/AIDS surveillance report. U.S. HIV and AIDS cases reported through December 2000, year end edition. 2000;12 (Accessed January 31, 2003 at www.cdc.gov/hiv/stats/hasr/202.htm).
12. Mocroft A, Madge S, Johnson AM, et al. A comparison of exposure groups in the EuroSIDA study: starting highly active antiretroviral therapy (HAART), response to HAART, and survival. J Acquir Immune Defic Syndr. 1999;22:369-378.
13. Roca B, Gomez CJ, Arnedo A. Stavudine, lamivudine and indinavir in drug abusing and non-drug abusing HIV-infected patients: adherence, side effects and efficacy. J Infect. 1999;39:141-145.
14. Palepu A, Yip B, Miller C, et al. Factors associated with the response to antiretroviral therapy among HIV-infected patients with and without a history of injection drug use. AIDS. 2001;15: 423-424.
15. Stein MD, Rich JD, Maksad J, et al. Adherence to antiretroviral therapy among HIV-infected methadone patients: effect of ongoing illicit drug use. Am J Drug Alcohol Abuse. 2000;26:195-205.
16. Lucas GM, Cheever LW, Chaisson RE, et al. Detrimental effects of continued illicit drug use on the treatment of HIV-1 infection. J Acquir Immune Defic Syndr. 2001;27:251-259.
17. Montaner JSG, O'Shaughnessy MV. Therapeutic guidelines for the treatment of HIV/AIDS and related conditions. Vancouver: British Columbia Centre for Excellence in HIV/AIDS, 1996.
18. Low-Beer S, Yip B, O'Shaughnessy MV, et al. Adherence to triple therapy and viral load response. J Acquir Immune Defic Syndr. 2000;23:360-361.
19. Hogg RS, Heath K, Bangsberg D, et al. Intermittent use of triple-combination therapy is predictive of mortality at baseline and after 1 year of follow-up. AIDS. 2002;16:1051-1058.
20. Neave H, Worthington P. Distribution-free tests. London: Routledge, 1998.
21. Arnsten JH, Demas PA, Grant RW, et al. Impact of active drug use on antiretroviral therapy adherence and viral suppression in HIV-infected drug users. J Gen Intern Med. 2002;17:377-3-81.
22. Moatti JP, Carrieri MP, Spire B, et al. Adherence to HAART in French HIV-infected injecting drug users: the contribution of buprenorphine drug maintenance treatment. The Manif 2000 study group. AIDS. 2000;14:151-155.
23. Arnsten JH, Demas PA, Farzadegan H, et al. Antiretroviral therapy adherence and viral suppression in HIV-infected drug users: comparison of self-report and electronic monitoring. Clin Infect Dis. 2001;33:1417-1423.
24. Lucas GM, Gebo KA, Chaisson RE, et al. Longitudinal assessment of the effects of drug and alcohol abuse on HIV-1 treatment outcomes in an urban clinic. AIDS. 2002;16:767-774.
25. Matthews GV, Sabin CA, Mandalia S, et al. Virological suppression at 6 months is related to choice of initial regimen in antiretroviral-naive patients: a cohort study. AIDS. 2002;16:53-61.
26. Torre D, Tambini R, Speranza F. Nevirapine or efavirenz combined with two nucleoside reverse transcriptase inhibitors compared to HAART: a meta-analysis of randomized clinical trials. HIV Clin Trials. 2001;2:113-121.
27. Ghani AC, Henley WE, Donnelly CA, et al. Comparison of the effectiveness of non-nucleoside reverse transcriptase inhibitorcontaining and protease inhibitor-containing regimens using observational databases. AIDS. 2001;15:1133-1142.
28. Zaccarelli M, Barracchini A, De Longis P, et al. Factors related to virologic failure among HIV-positive injecting drug users treated with combination antiretroviral therapy including two nucleoside reverse transcriptase inhibitors and nevirapine. AIDS Patient Care STDS. 2002;16:67-73.
29. Turner BJ, Newschaffer CJ, Zhang D, et al. Antiretroviral use and pharmacy-based measurement of adherence in postpartum HIV-infected women. Med Care. 2000;38:911-925.
30. Strathdee SA, Palepu A, Comelisse PG, et al. Barriers to use of free antiretroviral therapy in injection drug users. JAMA. 1998; 280:547-549.
31. Havlir D, Bassett R, Levitan D, et al. Prevalence and predictive value of intermittent viremia with combination HIV therapy. JAMA. 2001;286:171-179.